As we have seen, stereotactic body radiation therapy (SBRT) is a preferred therapy for low- and intermediate-risk patients (see this link). It is effective, safe, convenient, and relatively inexpensive. However, its use for high-risk patients remains controversial. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", intermediate risk, outcomes, radiation | Leave a comment »
It is becoming very clear that over the next 5 to 10 years we will develop a whole new spectrum of urine-based tests for the assessment of risk for prostate cancer and whether a specific patient will actually need a biopsy and/or other tests to confirm diagnosis. … READ MORE…
Filed under: Diagnosis, Risk | Tagged: future, risk, screening, test, urine | 1 Comment »
As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, disease, Mediterranean, progression, risk, surveillance | 4 Comments »
The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, low risk, Mediterranean, surveillance | 4 Comments »
Earlier today, the US Food and Drug Administration (FDA) approved relugolix, (Orgovyx, from Myovant Sciences), the first, oral luteinizing hormone releasing hormone (LHRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, GnRH, LHRH, Myovant, Orgovyx, relugolix | 6 Comments »
OK … so it took us a couple of days to work out why only two centers (at UCSF and UCLA) had been approved to administer the new (to the US) gallium-68 PSMA-11 scans. It wasn’t very smart of us. We should have realized immediately! … READ MORE …
Filed under: Management | Tagged: gallium-68, maunfacture, PSMA, scan | 10 Comments »
If you are one of our readers who is really “into” the underlying causes of and development of prostate cancer, then you probably want to see if you can read a newly published article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Uncategorized | Tagged: epigenetics, evolution, genetrics, initiation, progression | 2 Comments »
Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: gallium-68, imaging, PET, PSMA, scan | 5 Comments »
Some 18 months ago we had written about the possible occurrence of spontaneous remissions in men on active surveillance (AS) for low-risk forms of prostate cancer. We were therefore very interested in a recent article closely related to this topic. … READ MORE..
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, negative, remission, serial, spontaneous, surveillance | 14 Comments »
If you are someone who can spare a few bucks to support research into prostate cancer (and particularly the more aggressive forms of prostate cancer), please read on … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: donate, PCF, research | Leave a comment »
A recent report in the CDC’s Morbidity and Mortality Weekly Report (MMWR) may offer one of the best analyses of an increasing risk for diagnosis with and death from advanced forms of prostate cancer over the period from 2003 to 2017 (the last year for which we have accurate data from the SEER database). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CDC, Diagnosis, epidemiology, incidence, mortality, risk | 3 Comments »
Nearly 3 years ago now, we first mentioned a surgical technique known as “Retzius-sparing” radical prostatectomy on this web site. … READ MORE …
Filed under: Management, Treatment, Uncategorized | Tagged: hood, prostatectomy, radical, Retzius-sparing, surgery, technique | 1 Comment »
The following article was written by two of the founders of Active Surveillance Patients International (ASPI) under the title “Al Roker’s forecast: rising PSA and a radical prostatectomy” and distributed largely by e-mail. It is re-posted here with the permission of the authors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: active, celebrity, Roker, surveillance | 4 Comments »
